Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine + Mitoxantrone + Etoposide in Relapsed AML
NCT02631252Phase 1Terminated
- Start
- Aug 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hydroxychloroquine in acute myeloid leukemia (AML). Primary endpoint: Recommended Phase 2 Dose at 7 weeks. Started Aug 2016; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02631252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02631252.